Mechanistic basis for overcoming platinum resistance using copper chelating agents.
about
Role of copper transporters in platinum resistanceSystems biology of cisplatin resistance: past, present and futureDeterminants for simultaneous binding of copper and platinum to human chaperone Atox1: hitchhiking not hijackingMembrane transporters as mediators of Cisplatin effects and side effects.Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary CancerExpression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer.Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals.Copper transporter 2 regulates intracellular copper and sensitivity to cisplatinCisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1)Overcoming platinum drug resistance with copper-lowering agents.Role of transporters in the distribution of platinum-based drugs.Targeting copper in cancer therapy: 'Copper That Cancer'.The role of membrane transporters in ovarian cancer chemoresistance and prognosis.Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatmentMolecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics.Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.Effects of Cu(II) and cisplatin on the stability of Specific protein 1 (Sp1)-DNA binding: Insights into the regulation of copper homeostasis and platinum drug transport.Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo.Di-copper metallodrugs promote NCI-60 chemotherapy via singlet oxygen and superoxide production with tandem TA/TA and AT/AT oligonucleotide discrimination.Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy.Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.Synthesis and supramolecular assembly of 1,3-bis(1′-uracilyl)-2-propanoneAn Updated View of Cisplatin Transport
P2860
Q26767028-2DC43969-9250-4A35-8E0A-BDE589B477CEQ26863585-50EE6649-8785-4B19-9876-B22F9BE168C0Q28534972-5C2C64C6-4CA9-4881-897D-577A8D302407Q30446860-D918AAF5-F6E8-47DF-822D-E8A6B52F60EEQ33798999-AA51C6A5-40FA-4720-9F1D-0BA18276C6E6Q35558444-2ABC24DA-4EEB-4063-A4DA-22F720132102Q36085960-AB68568E-200C-4040-9C66-45BFB1B110FEQ36557426-860B8684-55C7-498D-9D64-1025F3C3D9CFQ36841450-C76697DD-F00C-4CB7-ADB4-AC1C44EBC0E6Q37470105-BEBBA842-728F-4E62-AC5D-BAA35847AC97Q37696191-53B708DD-7C64-4116-BB93-5AA6EF350013Q37696195-160DDA25-DA09-4E4C-96A5-BC7C5C94AF22Q37707059-163BEC15-F372-47D6-89D2-27462D27220AQ37727299-8F5106EE-D6F2-4F7C-AB2D-9B6C758A5429Q38474594-D0CE9A17-5A3B-41CD-984F-AA9B4CBFB517Q38575035-5B4A154D-D214-4E14-84A4-4F384C2CF733Q38683064-3E5BD190-CECC-44E3-A1AA-FD3ABF7E12F5Q38764239-30D959A2-A692-48D7-BB29-301877287F1BQ39121383-6E2E4F56-BB1D-469C-9232-632FEC79E91AQ39433258-553C6B2E-96BF-4A18-B7AE-2C73DD5AE485Q39785045-820F460F-EC3B-4376-AB42-882F0A921373Q42635385-41E10DB1-9DA2-4A70-80CF-9EA04E1AE099Q42708068-19E7EFA7-2665-4E46-B5F0-EA82AD735DC3Q42712071-E2824A28-E11D-4149-B5C0-61FF11D64DBBQ52374153-2460E9C8-B411-44EB-AFEE-DAE775786314Q53499541-4C04B1B0-2F52-404E-B4EC-2AEA53F1A821Q55091136-E7EE39D3-0751-4CD6-A24B-386D0415C742Q58466742-7BFA8A26-D178-4325-9E10-43B0F9353F03Q59172334-223F8490-344C-4ECC-A8FB-565431113D31
P2860
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
@ast
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
@en
type
label
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
@ast
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
@en
prefLabel
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
@ast
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
@en
P2093
P2860
P50
P1476
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
@en
P2093
Bryan T Hennessy
Gordon B Mills
Helen H W Chen
Macus Tien Kuo
Mihai Gagea-Iurascu
Niramol Savaraj
Wen-Bin Tsai
P2860
P304
P356
10.1158/1535-7163.MCT-12-0580
P577
2012-08-21T00:00:00Z